Sydney Lupkin, NPR

Sydney Lupkin

NPR

Washington, DC, United States

Contact Sydney

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • NPR
  • 88.5 WFDD
Past:
  • WFAE
  • KERA News
  • Kaiser Health News
  • CaliforniaHealthline
  • USA TODAY
  • ABC News
  • Philly.com
  • STAT
  • knkx public radio
  • WGBH
  • and more…

Recent articles by Sydney:

NPR

Pfizer's Coronavirus Vaccine Supply Contract Excludes Many Taxpayer Protections

The $1.95 billion Operation Warp Speed contract excludes government rights to inventions or production know-how developed in the manufacture of the COVID-19 vaccine. → Read More

NPR

Novavax Posts Coronavirus Vaccine Contract That Government Didn't Disclose

The $1.6 billion Novavax contract is one of several Operation Warp Speed agreements issued through a third party, Advanced Technology International, and that hadn't been released. → Read More

NPR

HHS Released More Coronavirus Vaccine Contracts As Election Results Unfolded

Newly released COVID-19 vaccine contracts include weakened protections against potential price gouging. Several key federal contracts still haven't been disclosed by the government. → Read More

Federal Supply Deal For COVID-19 Antibody Treatment Lacks Some Customary Protections

To boost the supply of Regeneron's antibody therapy for COVID-19, the federal government entered into a $450 million supply contract. Details of the deal show some safeguards are missing. → Read More

NPR

Federal Supply Deal For COVID-19 Antibody Treatment Lacks Some Customary Protections

To boost the supply of Regeneron's antibody therapy for COVID-19, the federal government entered into a $450 million supply contract. Details of the deal show some safeguards are missing. → Read More

NPR

After Months Of Questions, A Key Operation Warp Speed Adviser's Contract Emerges

Drug industry veteran Moncef Slaoui is a key figure in Operation Warp Speed's push to develop COVID-19 coronavirus vaccines. His employment terms raised concerns about potential conflicts of interest. → Read More

NPR

A Federal Coronavirus Vaccine Contract Released At Last, But Redactions Obscure Terms

Most of the federal contracts with companies involved in the crash program to make COVID-19 vaccines haven't been made public. The lack of disclosure raises questions about accountability. → Read More

NPR

Will FDA Heed Its Outside Experts' Advice On COVID-19 Vaccines?

A panel of doctor and scientists raised questions about the expedited regulatory path the Food and Drug Administration is considering for COVID-19 vaccines. → Read More

NPR

Call For Administration's COVID-19 Vaccine Contracts To Be Disclosed

Members of Congress and advocacy groups say Operation Warp Speed should release its contracts with vaccine makers after NPR reporting found the terms of many aren't public. → Read More

NPR

FDA Releases Long-Awaited COVID-19 Vaccine Guidance

The requirements laid out by the Food and Drug Administration in advice for drugmakers underscore why it's unlikely a vaccine could clear the agency before Election Day. → Read More

NPR

How Operation Warp Speed's Big Vaccine Contracts Could Stay Secret

More than $6 billion in federal funding has been routed through a firm that manages defense contracts, making the agreements subject to less federal scrutiny and transparency. → Read More

NPR

What To Know About Those $200 Drug Cards President Trump Promised

Health policy researchers say Trump may not be able to pay for the cards, which fall short of lasting policy changes to curb high drug prices. → Read More

What To Know About Those $200 Drug Cards President Trump Promised

Health policy researchers say Trump may not be able to pay for the cards, which fall short of lasting policy changes to curb high drug prices. → Read More

What To Know About Those $200 Drug Cards President Trump Promised

President Trump promised this week to send cards worth $200 to seniors to help them pay for their prescription drugs, but it's unclear how he will be → Read More

How Feds Decide On Remdesivir Shipments To States Remains Mysterious

By the second week in July, COVID-19 cases in North Carolina were climbing fast. With nearly 19,000 diagnoses over the previous two weeks, only five → Read More

NPR

How Feds Decide On Remdesivir Shipments To States Remains Mysterious

The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most? → Read More

Prices For COVID-19 Vaccines Are Starting To Come Into Focus

Moderna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower. → Read More

NPR

One Drug, Two Prices

Faced with the prospect of paying for an expensive drug to treat his daughter, this dad found a nearly identical product for thousands of dollars less. But the insurance company wouldn't let him. → Read More

NPR

Prices For COVID-19 Vaccines Are Starting To Come Into Focus

Moderna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower. → Read More

NPR

U.S. Reaches $2.1 Billion Deal With Sanofi, GlaxoSmithKline For COVID-19 Vaccine Push

This is the sixth vaccine candidate to join Operation Warp Speed's portfolio, and the largest vaccine deal to date. → Read More